EHRA Premium Access

Comparison of the efficacy and safety of injectable propafenone and amiodarone for elimination of paroxysmal atrial fibrillation in patients without organic heart disease.

Topic: Antiarrhythmic Drug Treatment

Congress Presentation

About the speaker

Doctor Alexey Tarasov

National Research Center for Preventive Medicine, Moscow (Russian Federation)
0 follower

6 more presentations in this session

Effect of efficient lipid-lowering atorvastatin therapy on heart rate variability in the post-infarction period

Speaker: Professor V. Oleinikov (Penza, RU)


QT dispersion in patients with myocardial infarction and high-dose therapy with atorvastatin

Speaker: Professor V. Oleinikov (Penza, RU)


Antiarrhythmic relevance of inhibiting cardiac and non-cardiac sodium channel isoforms for the suppression of torsades de pointes arrhythmias in the chronic av block dog

Speaker: Mr A. Bossu (Utrecht, NL)


Analysis of predictive factors for propafenone proarrythmia. Does exercise ECG play a role during long term propafenone treatment?

Speaker: Mr P. Kalmar (Debrecen, HU)


Venous thrombosis in patients after catheter ablation.Efficacy and safety of enoxaparin therapy with the transition to warfarin and monotherapy with rivaroxaban

Speaker: Miss A. Loginova (Moscow, RU)


Access the full session

Poster session 2 - Arrhythmias

Speakers: Doctor A. Tarasov, Professor V. Oleinikov, Professor V. Oleinikov, Mr A. Bossu, Mr P. Kalmar...

About the event


EHRA 2019

17 March - 19 March 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb